Patient characteristics
| Patient characteristics . | Total (N = 90) . |
|---|---|
| Age at CAR T-cell infusion, median (range), y | 49 (18-75) |
| Diagnosis, n (%) | |
| B-ALL | 10 (11%) |
| NHL | 80 (89%) |
| DLBCL | 56 (62%) |
| PMBCL | 11 (12%) |
| TFL | 8 (9%) |
| MCL | 5 (6%) |
| CAR T-cell product, n (%) | |
| Axicabtagene ciloleucel | 42 (47%) |
| Tisagenlecleucel | 37 (41%) |
| Brexucabtagene autoleucel | 11 (12%) |
| Prior lines of treatment, median (range) | 3 (1-9) |
| Previous autologous transplantation | 13 (15%) |
| Previous allogeneic transplantation | 7 (8%) |
| CRS or ICANS | |
| CRS grade ≥3 | 19 (21%) |
| ICANS grade ≥3 | 32 (34%) |
| Laboratory findings at baseline (range) | |
| LDH, IU/L | 248 (125-1411) |
| Creatinine, mg/dL | 0.8 (0.39-7.0) |
| PLTs, × 109 cells per L | 77.5 (16.0-314) |
| CRP, mg/dL | 6.1 (0.28-86.3) |
| Patient characteristics . | Total (N = 90) . |
|---|---|
| Age at CAR T-cell infusion, median (range), y | 49 (18-75) |
| Diagnosis, n (%) | |
| B-ALL | 10 (11%) |
| NHL | 80 (89%) |
| DLBCL | 56 (62%) |
| PMBCL | 11 (12%) |
| TFL | 8 (9%) |
| MCL | 5 (6%) |
| CAR T-cell product, n (%) | |
| Axicabtagene ciloleucel | 42 (47%) |
| Tisagenlecleucel | 37 (41%) |
| Brexucabtagene autoleucel | 11 (12%) |
| Prior lines of treatment, median (range) | 3 (1-9) |
| Previous autologous transplantation | 13 (15%) |
| Previous allogeneic transplantation | 7 (8%) |
| CRS or ICANS | |
| CRS grade ≥3 | 19 (21%) |
| ICANS grade ≥3 | 32 (34%) |
| Laboratory findings at baseline (range) | |
| LDH, IU/L | 248 (125-1411) |
| Creatinine, mg/dL | 0.8 (0.39-7.0) |
| PLTs, × 109 cells per L | 77.5 (16.0-314) |
| CRP, mg/dL | 6.1 (0.28-86.3) |
B-ALL, B-cell acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; NHL, non-Hodgkin lymphoma; PMBCL, primary mediastinal large B-cell lymphoma; TFL, transformed follicular lymphoma.